Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of V116 in pneumococcal vaccine-experienced adults aged 50 years or older
2021-006679-41Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-arm trial of pneumococcal 21-valent conjugate vaccine in pneumococcal disease, sponsored by Merck & Co. Primary endpoint: Number of participants with a solicited injection-site adverse event from Day 1 through Day 5 postvaccination. Started May 2022; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2021-006679-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006679-41.